Free tool
FAERS Monitor: Dyrenium
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 013174 or its brand name (Dyrenium, Triamterene). Reports on generic versions are filed under their own applications.
Reports
7,328
Serious
4,003
55% of reports
Hospitalization
1,813
Death reported
414
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease479
- fatigue476
- drug ineffective453
- pain439
- nausea420
- diarrhoea405
- dyspnoea348
- dizziness345
- renal failure329
- headache327
- arthralgia314
- acute kidney injury308
- off label use270
- asthenia261
- fall259
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 144 |
| 2005 | 178 |
| 2006 | 154 |
| 2007 | 133 |
| 2008 | 152 |
| 2009 | 237 |
| 2010 | 323 |
| 2011 | 295 |
| 2012 | 312 |
| 2013 | 280 |
| 2014 | 384 |
| 2015 | 538 |
| 2016 | 487 |
| 2017 | 475 |
| 2018 | 664 |
| 2019 | 599 |
| 2020 | 405 |
| 2021 | 364 |
| 2022 | 308 |
| 2023 | 237 |
| 2024 | 237 |
| 2025 | 225 |
| 2026 | 197 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,831 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 479 | 18.2 | 16.7 | 7,749 |
| renal failureSignal | 329 | 7.1 | 6.4 | 1,733 |
| acute kidney injurySignal | 308 | 5.8 | 5.2 | 1,221 |
| fallSignal | 259 | 2.2 | 2.0 | 178 |
| arthralgiaSignal | 314 | 2.2 | 1.9 | 200 |
| painSignal | 439 | 2.1 | 1.9 | 243 |
| asthenia | 261 | 2.0 | 1.8 | 130 |
| dizziness | 345 | 2.0 | 1.8 | 172 |
| diarrhoea | 405 | 1.8 | 1.6 | 148 |
| dyspnoea | 348 | 1.8 | 1.6 | 118 |
| fatigue | 476 | 1.8 | 1.6 | 160 |
| nausea | 420 | 1.5 | 1.4 | 78 |
| headache | 327 | 1.5 | 1.3 | 55 |
| drug ineffective | 453 | 1.0 | 0.9 | 0 |
| off label use | 270 | 0.9 | 0.8 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.